Patents by Inventor Sayee Gajanan Hegde

Sayee Gajanan Hegde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREPARATION OF AN SELECTIVE ESTROGEN RECEPTOR DEGRADER
    Publication number: 20230212118
    Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.
    Type: Application
    Filed: April 21, 2021
    Publication date: July 6, 2023
    Inventors: Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, John Knight, Joseph Robert Pinchman, Aditya Krishnan Unni, Rakesh Kumar Sit, Shuguang Zhu, Chad Daniel Hopkins, Ian Scott
  • COMBINATIONS
    Publication number: 20230087941
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: March 23, 2023
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Peter Qinhua Huang, Sayee Gajanan Hegde, Brant Clayton Boren, Kevin Duane Bunker, Fernando Donate
  • COMBINATIONS
    Publication number: 20230053946
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and another inhibitor (such as a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, a BET inhibitor and an Aurora inhibitor), along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 23, 2023
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, Fernando Donate
  • COMBINATIONS
    Publication number: 20230054767
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 23, 2023
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Hooman Izadi, Peter Qinhua Huang, Sayee Gajanan Hegde, Joseph Robert Pinchman, Kevin Duane Bunker, Fernando Donate
  • COMBINATIONS
    Publication number: 20230042653
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 9, 2023
    Inventors: Ahmed Abdi Samatar, Jianhui Ma, Jiali Li, Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, Fernando Donate
  • SALTS AND FORMS OF AN ESTROGEN RECEPTOR MODULATOR
    Publication number: 20220389006
    Abstract: Salts of Compound A and forms described herein are estrogen receptor alpha modulators. Such salts and/or forms can be are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: November 2, 2020
    Publication date: December 8, 2022
    Inventors: Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, John Knight, Deborah Helen Slee
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20220235050
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.
    Type: Application
    Filed: April 4, 2022
    Publication date: July 28, 2022
    Inventors: Guobao Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sayee Gajanan Hegde
  • Estrogen receptor modulators
    Patent number: 11339162
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: May 24, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Guobao Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sayee Gajanan Hegde
  • ESTROGEN RECEPTOR MODULATORS FOR TREATING MUTANTS
    Publication number: 20220125769
    Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).
    Type: Application
    Filed: January 5, 2022
    Publication date: April 28, 2022
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate
  • Estrogen receptor modulators for treating mutants
    Patent number: 11278532
    Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: March 22, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate
  • Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
    Patent number: 11261192
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: March 1, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20220024939
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 27, 2022
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20210330651
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • Estrogen receptor modulators
    Patent number: 11065233
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • Estrogen receptor modulators
    Patent number: 11065234
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20210139482
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: February 26, 2019
    Publication date: May 13, 2021
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • ACRYLIC ACID ANALOGS
    Publication number: 20210094899
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 26, 2018
    Publication date: April 1, 2021
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Kevin Duane Bunker, Sayee Gajanan Hegde, Chad Daniel Hopkins
  • Estrogen receptor modulators
    Patent number: 10959989
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 30, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • ESTROGEN RECEPTOR MODULATORS FOR TREATING MUTANTS
    Publication number: 20210038573
    Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).
    Type: Application
    Filed: August 4, 2020
    Publication date: February 11, 2021
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20200261428
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: May 5, 2020
    Publication date: August 20, 2020
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit